



an Open Access Journal by MDPI

Recent Advances in Ischemic Heart Diseases

Guest Editors:

Dr. Vinay Kumar

Department of Physiology and
Cell Biology, The Ohio State
University Wexner Medical
Center, Columbus, OH 43210,
USA

Dr. Surendra Kumar Shukla

Department of Oncology Science,
OU Health Stephenson Cancer
Centre, Oklahoma City, OK 73104,
USA

Deadline for manuscript
submissions:

closed (31 October 2023)

Message from the Guest Editors

Dear Colleagues,

Ischemic heart disease typically leads to heart failure, which can exacerbate impaired quality of life, socioeconomic burden and is the leading cause of death worldwide. Myocardial necrosis, myocardial shock, and mechanical problems such as ventricular septal defect, papillary muscle rupture, and ventricular free wall rupture all underwrite the pathophysiology of ischemic heart failure development at the time of the myocardial infarction hospitalization. Henceforth, substantial advances are desirable to control the risk factors and search for new therapies, drug development, rapid improvement in immunotherapy technology, the emergence of new clinical trials and interventions including bypass surgery and stent placement.

We kindly invite all scholars to submit original research articles and reviews on any issue pertinent to ischemic heart failure studies for this Special Issue. The theme focuses on the unique molecular and cellular roles of cardiac health management, development of novel techniques, advances in the current clinical scenario, and newly developing strategies on a variety of cardiovascular diseases.



mdpi.com/si/172210

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI